{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:24:05Z","timestamp":1725150245864},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,31]]},"DOI":"10.7759\/cureus.68274","type":"journal-article","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T09:19:05Z","timestamp":1725095945000},"source":"Crossref","is-referenced-by-count":0,"title":["Finerenone\u2019s Impact on Major Adverse Cardiovascular Events in Chronic Kidney Disease and Type 2 Diabetes Mellitus: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Vignesh","family":"Murugan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhana","family":"Nazmin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjana","family":"Singareddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surakchhya","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Therese Anne","family":"Limba\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy CP","year":"2022","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022, 12:7-11. 10.1016\/j.kisu.2021.11.003","journal-title":"Kidney Int Suppl (2011)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01440-5","article-title":"Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review","volume":"21","author":"Bosco E","year":"2021","unstructured":"Bosco E, Hsueh L, McConeghy KW, Gravenstein S, Saade E. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Med Res Methodol. 2021, 21:241. 10.1186\/s12874-021-01440-5","journal-title":"BMC Med Res Methodol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22189995","article-title":"Mineralocorticoid receptor antagonists-use in chronic kidney disease","volume":"22","author":"Baran W","year":"2021","unstructured":"Baran W, Krzemi\u0144ska J, Szlagor M, Wronka M, M\u0142ynarska E, Franczyk B, Rysz J. Mineralocorticoid receptor antagonists-use in chronic kidney disease. Int J Mol Sci. 2021, 22:9995. 10.3390\/ijms22189995","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ph17040418","article-title":"Finerenone: Ffrom the mechanism of action to clinical use in kidney disease","volume":"17","author":"Piko N","year":"2024","unstructured":"Piko N, Bevc S, Hojs R, Ekart R. Finerenone: Ffrom the mechanism of action to clinical use in kidney disease. Pharmaceuticals (Basel). 2024, 17:418. 10.3390\/ph17040418","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris GL","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al.. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020, 383:2219-29. 10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1159\/000532102","article-title":"Cardiorenal outcomes with finerenone in Asian patients with chronic kidney disease and type 2 diabetes: A FIDELIO-DKD post hoc analysis","volume":"54","author":"Koya D","year":"2023","unstructured":"Koya D, Anker SD, Ruilope LM, et al.. Cardiorenal outcomes with finerenone in Asian patients with chronic kidney disease and type 2 diabetes: A FIDELIO-DKD post hoc analysis. Am J Nephrol. 2023, 54:370-8. 10.1159\/000532102","journal-title":"Am J Nephrol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal R","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, et al.. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022, 43:474-84. 10.1093\/eurheartj\/ehab777","journal-title":"Eur Heart J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt B","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, et al.. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021, 385:2252-63. 10.1056\/NEJMoa2110956","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"143","author":"Filippatos G","year":"2021","unstructured":"Filippatos G, Anker SD, Agarwal R, et al.. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Circulation. 2021, 143:540-52. 10.1161\/CIRCULATIONAHA.120.051898","journal-title":"Circulation"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-076444","article-title":"Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials","volume":"14","author":"Bansal S","year":"2024","unstructured":"Bansal S, Canziani ME, Birne R, et al.. Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials. BMJ Open. 2024, 14:e076444. 10.1136\/bmjopen-2023-076444","journal-title":"BMJ Open"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2469","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial","volume":"24","author":"Filippatos G","year":"2022","unstructured":"Filippatos G, Pitt B, Agarwal R, et al.. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. Eur J Heart Fail. 2022, 24:996-1005. 10.1002\/ejhf.2469","journal-title":"Eur J Heart Fail"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvac054","article-title":"Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease","volume":"9","author":"Filippatos G","year":"2022","unstructured":"Filippatos G, Anker SD, Pitt B, et al.. Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease. Eur Heart J Cardiovasc Pharmacother. 2022, 9:85-93. 10.1093\/ehjcvp\/pvac054","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.41746","article-title":"A systematic review and meta-analysis on the efficacy and safety of finerenone therapy in patients with cardiovascular and chronic kidney diseases in type 2 diabetes mellitus","volume":"15","author":"Jyotsna F","year":"2023","unstructured":"Jyotsna F, Mahfooz K, Patel T, et al.. A systematic review and meta-analysis on the efficacy and safety of finerenone therapy in patients with cardiovascular and chronic kidney diseases in type 2 diabetes mellitus. Cureus. 2023, 15:e41746. 10.7759\/cureus.41746","journal-title":"Cureus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5582\/irdr.2020.01008","article-title":"The cardiovascular outcomes of finerenone in patients with chronic kidney disease and type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"11","author":"Abdelazeem B","year":"2022","unstructured":"Abdelazeem B, Elbadawy MA, Awad AK, Kheiri B, Kunadi A. The cardiovascular outcomes of finerenone in patients with chronic kidney disease and type 2 diabetes: a meta-analysis of randomized clinical trials. Intractable Rare Dis Res. 2022, 11:31-3. 10.5582\/irdr.2020.01008","journal-title":"Intractable Rare Dis Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1159\/000534071","article-title":"Disease burden and epidemiological trends of chronic kidney disease at the global, regional, national levels from 1990 to 2019","volume":"148","author":"Ying M","year":"2024","unstructured":"Ying M, Shao X, Qin H, et al.. Disease burden and epidemiological trends of chronic kidney disease at the global, regional, national levels from 1990 to 2019. Nephron. 2024, 148:113-23. 10.1159\/000534071","journal-title":"Nephron"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/nu13093277","article-title":"Chronic kidney disease: role of diet for a reduction in the severity of the disease","volume":"13","author":"Naber T","year":"2021","unstructured":"Naber T, Purohit S. Chronic kidney disease: role of diet for a reduction in the severity of the disease. Nutrients. 2021, 13:3277. 10.3390\/nu13093277","journal-title":"Nutrients"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.14745","article-title":"Chronic kidney disease diagnosis and management: a review","volume":"322","author":"Chen TK","year":"2019","unstructured":"Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. JAMA. 2019, 322:1294-304. 10.1001\/jama.2019.14745","journal-title":"JAMA"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2018.02.007","article-title":"Update of pathophysiology and management of diabetic kidney disease","volume":"117","author":"Lin YC","year":"2018","unstructured":"Lin YC, Chang YH, Yang SY, Wu KD, Chu TS. Update of pathophysiology and management of diabetic kidney disease. J Formos Med Assoc. 2018, 117:662-75. 10.1016\/j.jfma.2018.02.007","journal-title":"J Formos Med Assoc"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens PE","year":"2024","unstructured":"Stevens PE, Ahmed SB, Carrero JJ, et al.. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024, 105:S117-314. 10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.33939","article-title":"Sodium-glucose cotransporter 2 (SGLT2) Inhibitors: benefits versus risk","volume":"15","author":"Jasleen B","year":"2023","unstructured":"Jasleen B, Vishal GK, Sameera M, Fahad M, Brendan O, Deion S, Pemminati S. Sodium-glucose cotransporter 2 (SGLT2) Inhibitors: benefits versus risk. Cureus. 2023, 15:e33939. 10.7759\/cureus.33939","journal-title":"Cureus"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-022-01492-w","article-title":"Real-world evidence for steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease","volume":"36","author":"Folkerts K","year":"2023","unstructured":"Folkerts K, Millier A, Smela B, Olewinska E, Schmedt N, Mernagh P, Kovesdy CP. Real-world evidence for steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease. J Nephrol. 2023, 36:1135-67. 10.1007\/s40620-022-01492-w","journal-title":"J Nephrol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpac124","article-title":"The nonsteroidal mineralocorticoid-receptor-antagonist finerenone in cardiorenal medicine: A state-of-the-art review of the literature","volume":"36","author":"Georgianos PI","year":"2023","unstructured":"Georgianos PI, Agarwal R. The nonsteroidal mineralocorticoid-receptor-antagonist finerenone in cardiorenal medicine: A state-of-the-art review of the literature. Am J Hypertens. 2023, 36:135-43. 10.1093\/ajh\/hpac124","journal-title":"Am J Hypertens"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12123992","article-title":"Finerenone: Questions and answers-the four fundamental arguments on the new-born promising non-steroidal mineralocorticoid receptor antagonist","volume":"12","author":"Di Lullo L","year":"2023","unstructured":"Di Lullo L, Lavalle C, Scatena A, Mariani MV, Ronco C, Bellasi A. Finerenone: Questions and answers-the four fundamental arguments on the new-born promising non-steroidal mineralocorticoid receptor antagonist. J Clin Med. 2023, 12:3992. 10.3390\/jcm12123992","journal-title":"J Clin Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/290631-finerenones-impact-on-major-adverse-cardiovascular-events-in-chronic-kidney-disease-and-type-2-diabetes-mellitus-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T09:19:08Z","timestamp":1725095948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/290631-finerenones-impact-on-major-adverse-cardiovascular-events-in-chronic-kidney-disease-and-type-2-diabetes-mellitus-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,31]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.68274","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,31]]}}}